<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05094934</url>
  </required_header>
  <id_info>
    <org_study_id>NN6435-4749</org_study_id>
    <secondary_id>U1111-1264-2693</secondary_id>
    <secondary_id>2021-000462-16</secondary_id>
    <nct_id>NCT05094934</nct_id>
  </id_info>
  <brief_title>A Research Study Looking Into Levels of the Medicine NNC0385-0434 in the Body and How Well it is Tolerated in Participants With Impaired Kidney Function Compared to Participants With Normal Kidney Function</brief_title>
  <official_title>Investigation of Pharmacokinetics, Safety and Tolerability of Oral NNC0385-0434 in Participants With Various Degrees of Impaired Renal Function and in Participants With Normal Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novo Nordisk is developing a new medicine, NNC0385-0434, to help people lower their&#xD;
      cholesterol level.&#xD;
&#xD;
      The aim of this study is to look at how NNC0385-0434 works in the body and how it is removed&#xD;
      from the body in people with impaired kidney function.&#xD;
&#xD;
      All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434,&#xD;
      which will be given for 10 days in a row. Participants will get the study medicine in a&#xD;
      tablet taken orally once-daily. The study medicine needs to be taken in the morning after&#xD;
      overnight fasting and 30 minutes before the first meal of the day.&#xD;
&#xD;
      The study will last for about 9-14 weeks.&#xD;
&#xD;
      Participants will have 15 visits to the study centre, including 2 in-house stays of 3 days&#xD;
      and 2 nights and 13 ambulatory visits.&#xD;
&#xD;
      Participants' vital signs (heart rate, blood pressure, body temperature) will be measured,&#xD;
      participants will have blood draws, urine will be collected and electrocardiograms (ECGs)&#xD;
      will be recorded.&#xD;
&#xD;
      Participants cannot take part in the study if they have gastrointestinal disorders or unusual&#xD;
      meal habits and special dietary requirements.&#xD;
&#xD;
      Women can only take part in the study if they cannot get pregnant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 9, 2021</start_date>
  <completion_date type="Anticipated">September 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-24h,0434,Day10: the area under the NNC0385-0434 plasma concentration-time curve from time 0 to 24 hours after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 24 hours post treatment (Day 11)</time_frame>
    <description>Measured in h*nmol/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax,0434,Day10: the maximum plasma concentration of NNC0385-0434 after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to post treatment follow-up (Day 65)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,0434,Day10: time from last dose administration to maximum plasma concentration of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to post treatment follow-up (Day 65)</time_frame>
    <description>h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,0434,Day10; the terminal half-life of NNC0385-0434 after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to post treatment follow-up (Day 65)</time_frame>
    <description>h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,0434,Day10; the renal clearance of NNC0385-0434 after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 48 hours post treatment (Day 12)</time_frame>
    <description>mL/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F0434,Day10; the apparent clearance of NNC0385-0434 after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (day 10) to post treatment follow-up (day 65)</time_frame>
    <description>mL/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F0434,Day10; the apparent volume of distribution of NNC0385-0434 in the terminal phase</measure>
    <time_frame>From last dose (Day 10) to post treatment follow-up (Day 65)</time_frame>
    <description>L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24h,SNAC,Day10: the area under the SNAC plasma concentration-time curve from time 0 to 24 hours after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 24 hours post treatment (Day 11)</time_frame>
    <description>h*nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,SNAC,Day10; the maximum plasma concentration of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 24 hours post treatment (Day 11)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,SNAC,Day10; the minimum plasma concentration of SNAC before last dose of oral NNC0385-0434</measure>
    <time_frame>Pre-dose (Day 10)</time_frame>
    <description>nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax,SNAC,Day10; the time to maximum observed plasma concentration of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 24 hours post treatment (Day 11)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t½,SNAC,Day10; the terminal half-life of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 24 hours post treatment (Day 11)</time_frame>
    <description>hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,SNAC,Day10; the renal clearance of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 48 hours post treatment (Day 12)</time_frame>
    <description>mL/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/FSNAC,Day10; the apparent clearance of SNAC after last dose of oral NNC0385-0434</measure>
    <time_frame>From last dose (Day 10) to 24 hours post treatment (Day 11)</time_frame>
    <description>mL/h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/FSNAC,Day10; the apparent volume of distribution of SNAC in the terminal phase</measure>
    <time_frame>From last dose (Day 10) to 24 hours post treatment (Day 11)</time_frame>
    <description>L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From first dose (Day 1) until completion of the post-treatment period at follow-up (Day 65)</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mildly decreased renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderately decreased renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severely decreased renal function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive 100 mg of NNC0385-0434 in an oral tablet per day for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0385-0434 A 100 mg</intervention_name>
    <description>All participants will receive the same dose (100 mg) of the study medicine NNC0385-0434, which will be given for 10 days in a row. Participants will get the study medicine in a tablet taken orally once-daily. The study medicine needs to be taken in the morning after overnight fasting and 30 minutes before the first meal of the day.</description>
    <arm_group_label>Mildly decreased renal function</arm_group_label>
    <arm_group_label>Moderately decreased renal function</arm_group_label>
    <arm_group_label>Normal renal function</arm_group_label>
    <arm_group_label>Severely decreased renal function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) between 20.0 and 34.9 kg/m^2 (both inclusive).&#xD;
&#xD;
          -  Meeting the pre-defined estimated glomerular filtration rate (eGFR) values based on&#xD;
             the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation according to&#xD;
             KDIGO 2012:&#xD;
&#xD;
        Group description eGFR (mL/min)&#xD;
&#xD;
          1. Normal renal function more than or equal to 90&#xD;
&#xD;
          2. Mildly decreased renal function 60 - less than 90&#xD;
&#xD;
          3. Moderately decreased renal function 30 - less than 60&#xD;
&#xD;
          4. Severely decreased renal function less than 30 not requiring dialysis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of clinically significant gastrointestinal disorders potentially affecting&#xD;
             absorption of drugs and/or nutrients, as judged by the study doctor.&#xD;
&#xD;
          -  Unusual meal habits and special dietary requirements or unwillingness to eat the food&#xD;
             provided in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (dept. 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

